Martee L Hensley Selected Research

Leiomyosarcoma

1/2021	Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma.
1/2020	Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.
1/2019	A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.
1/2019	Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
10/2018	Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study.
1/2018	Options for Adjuvant Therapy for Uterine Leiomyosarcoma.
1/2018	ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity.
1/2017	A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
1/2017	Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
3/2016	Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martee L Hensley Research Topics

Disease

46	Neoplasms (Cancer) 04/2022 - 04/2002
22	Ovarian Neoplasms (Ovarian Cancer) 07/2022 - 03/2002
22	Leiomyosarcoma 01/2021 - 06/2002
13	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 07/2007
9	Ovarian Epithelial Carcinoma 05/2012 - 03/2002
7	Disease Progression 01/2019 - 10/2003
5	Endometrial Stromal Sarcoma 04/2022 - 01/2017
5	Carcinosarcoma 01/2022 - 11/2008
5	Neutropenia 06/2013 - 08/2007
4	Endometrial Neoplasms (Endometrial Cancer) 01/2020 - 11/2006
4	Carcinoma (Carcinomatosis) 06/2014 - 03/2002
3	Hypertension (High Blood Pressure) 07/2022 - 12/2011
3	Breast Neoplasms (Breast Cancer) 01/2022 - 05/2005
3	Liposarcoma 01/2019 - 03/2016
3	Hypersensitivity (Allergy) 01/2018 - 03/2002
3	Thrombocytopenia (Thrombopenia) 01/2017 - 10/2008
3	Nausea 02/2016 - 04/2003
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2003 - 04/2003
2	Neurofibrosarcoma (MPNST) 01/2019 - 07/2009
2	Fatigue 06/2013 - 12/2012
2	Testicular Neoplasms (Testicular Cancer) 12/2012 - 05/2008
2	Lymphoma (Lymphomas) 12/2012 - 03/2007
2	Febrile Neutropenia 10/2008 - 08/2007
2	Exanthema (Rash) 08/2008 - 04/2003
2	Edema (Dropsy) 06/2003 - 04/2003
1	Cognitive Dysfunction 04/2022
1	Lymphadenopathy 01/2022
1	Synovial Sarcoma (Synovioma) 01/2019
1	Fever (Fevers) 01/2019
1	Leiomyoma (Uterine Fibroids) 01/2019
1	Microsatellite Instability 12/2018
1	Leukopenia 01/2017
1	Neoplasm Metastasis (Metastasis) 01/2017
1	Anemia 01/2017

Drug/Important Bio-Agent (IBA)

14	Gemcitabine FDA Link 10/2018 - 06/2002
11	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 03/2002
11	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 03/2002
10	Docetaxel (Taxotere)FDA Link 10/2018 - 06/2002
8	PlatinumIBA 01/2018 - 03/2002
7	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2018 - 06/2002
5	TrabectedinIBA 01/2019 - 01/2012
5	Cisplatin (Platino)FDA LinkGeneric 06/2012 - 03/2002
4	AntigensIBA 07/2022 - 07/2007
4	Dacarbazine (DIC)FDA LinkGeneric 01/2019 - 03/2016
3	Bevacizumab (Avastin)FDA Link 07/2022 - 12/2011
3	VaccinesIBA 07/2022 - 07/2007
3	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 12/2018
3	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2018
3	Cyclin D1IBA 01/2021 - 01/2018
3	DesminIBA 01/2021 - 01/2018
3	Progesterone Receptors (Progesterone Receptor)IBA 01/2020 - 03/2012
3	Imatinib Mesylate (Gleevec)FDA Link 10/2003 - 04/2003
2	Combined VaccinesIBA 07/2022 - 07/2007
2	Aromatase InhibitorsIBA 04/2022 - 03/2010
2	Hormones (Hormone)IBA 01/2022 - 01/2012
2	MART-1 AntigenIBA 01/2022 - 01/2021
2	Ifosfamide FDA LinkGeneric 01/2022 - 12/2011
2	Phosphotransferases (Kinase)IBA 01/2021 - 07/2009
2	Estrogen ReceptorsIBA 01/2020 - 01/2019
2	Sorafenib (BAY 43-9006)FDA Link 01/2019 - 07/2009
2	AnthracyclinesIBA 01/2017 - 03/2016
2	Hemoglobins (Hemoglobin)IBA 02/2016 - 11/2005
2	pazopanib FDA Link 07/2014 - 06/2014
2	Epothilones (Epothilone)IBA 12/2012 - 03/2007
2	desoxyepothilone B (epothilone D)IBA 12/2012 - 08/2012
2	Tumor Biomarkers (Tumor Markers)IBA 12/2012 - 05/2005
2	Peptides (Polypeptides)IBA 12/2012 - 05/2008
2	Folic Acid (Vitamin M)FDA LinkGeneric 11/2010 - 10/2008
2	Pharmaceutical PreparationsIBA 06/2008 - 06/2003
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2008 - 06/2008
2	ixabepilone (BMS 247550)FDA Link 08/2007 - 03/2007
2	EnzymesIBA 02/2007 - 08/2004
2	Biomarkers (Surrogate Marker)IBA 02/2007 - 08/2004
2	ImmunosorbentsIBA 02/2007 - 08/2004
2	Interferon-alpha (Interferon Alfa)IBA 10/2003 - 06/2003
2	Cytarabine (Cytosar-U)FDA LinkGeneric 10/2003 - 06/2003
1	LigandsIBA 01/2022
1	Cathepsin KIBA 01/2022
1	Biological ProductsIBA 01/2022
1	LY3023414IBA 01/2020
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2020
1	Angiogenesis InhibitorsIBA 01/2019
1	Immune Checkpoint InhibitorsIBA 01/2019
1	Proteins (Proteins, Gene)FDA Link 12/2018
1	Calmodulin-Binding Proteins (Caldesmon)IBA 01/2018
1	CollagenIBA 01/2018
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2017
1	MLN 8237IBA 01/2017
1	Alanine (L-Alanine)FDA Link 01/2017

Therapy/Procedure

33	Therapeutics 01/2022 - 03/2002
26	Drug Therapy (Chemotherapy) 04/2022 - 03/2002
6	Adjuvant Chemotherapy 10/2018 - 05/2005
3	Salpingo-oophorectomy 01/2020 - 06/2003
3	Radiotherapy 01/2017 - 01/2009
2	Morcellation 01/2021 - 01/2019
2	Retreatment 03/2010 - 03/2002
1	Hysterectomy 01/2022
1	Lymph Node Excision (Lymph Node Dissection) 01/2022
1	Drug Tapering 01/2019
1	Operative Surgical Procedures 01/2017